Regulatory Guidance & Policy

---

Regulatory bodies in the US, EU, and internationally are increasingly encouraging the responsible integration of New Approach Methodologies (NAMs) into nonclinical development and safety assessment. Below is a curated overview of key regulatory initiatives, guidance concepts, and policy frameworks relevant to cardiac NAM platforms.

The U.S. FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) program provides a pathway for qualification of innovative drug development tools (DDTs) that may not fit existing DDT qualification programs but can still improve drug development and regulatory decision-making. ISTAND supports approaches spanning experimental and computational methodologies and clarifies submission stages and expectations (e.g., LOI → Qualification Plan).

External links

• FDA ISTAND program overview 
• FDA ISTAND submission process (stages and requirements)
• FDA Qualification Process for Drug Development Tools
• FDA perspective on making ISTAND a permanent qualification program
   

The European Medicines Agency (EMA) frames NAMs as methods aligned with the 3Rs (Replacement, Reduction, Refinement) and supports their regulatory acceptance when scientifically sound and appropriate for decision-making. EMA provides guidance on how to interact with EMA regarding NAM acceptance and outlines considerations for achieving acceptance, including context of use, validation expectations, and evidentiary standards.

External links

• EMA page on regulatory acceptance of NAMs and interaction pathways 
• EMA overview page on ethical use of animals and NAMs (3Rs framing) 
• EMA horizon scanning report on NAM state-of-the-art and regulatory considerations 

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s national regulator responsible for ensuring the safety, quality, and efficacy of medicines and medical devices. MHRA provides scientific advice services and regulatory guidance at various stages of drug development, including early engagement on nonclinical and first-in-human strategies. Through its scientific advice programs, companies can request input on the design and interpretation of nonclinical data packages, including data derived from NAMs, to better align with regulatory expectations. MHRA is also participating in global efforts to reduce animal testing and endorse scientifically justified non-animal data in support of clinical decision-making, with strategic initiatives planned to issue guidance on the use of non-animal data for First-Time-in-Human studies by 2026.

External links

• MHRA scientific advice overview — Medicines: get scientific advice from MHRA
• MHRA and alternative methods roadmap (industry perspective)
• MHRA regulatory homepage (guidelines and updates)

In China, the National Medical Products Administration (NMPA) is the central authority responsible for regulating drugs, biologics, and medical devices under a framework that increasingly emphasizes scientific innovation and modern regulatory science. In 2019, the NMPA issued a Regulatory Science Action Plan aimed at advancing the use of scientific tools and methodologies to improve regulatory decision-making, transparency, and public health protection. This initiative seeks to modernize regulatory tools, standards, and methods — including mechanisms for incorporating human-relevant approaches and data — as part of broader efforts to strengthen drug safety evaluation and promote innovation within the pharmaceutical sector. Regulatory science priorities encompass new tools, real-world evidence, and emerging technologies, reflecting a strategic shift toward data-driven and human-relevant assessment methods aligned with global regulatory trends. 

External links

• NMPA’s official site (regulations, guidance, and updates)
• China accepts certain non-animal testing methods (IIVS)
• Regulatory roadmap and safety assessment in China (industry summary)

CiPA is an international initiative established to advance a more mechanistic paradigm for assessing proarrhythmic risk beyond traditional reliance on hERG block plus Thorough QT studies. CiPA integrates multi-ion channel pharmacology, in silico ventricular myocyte modeling, and confirmation in human stem cell–derived cardiomyocytes, aiming to improve specificity for torsadogenic risk assessment. 

External links

• CiPA initiative overview (project background and objectives) 
• Foundational CiPA publication (Colatsky et al.) 
• FDA resource describing CiPA’s multi-channel + in silico paradigm 

The OECD supports international harmonization through guidance and forums related to Testing and Assessment Methodologies, including NAM-relevant workstreams. OECD resources commonly emphasize integrated decision frameworks (e.g., IATA — Integrated Approaches to Testing and Assessment) and provide educational materials such as webinar series for regulators and CROs to learn about evolving standards and approaches. 

External links

• OECD Testing and Assessment Methodologies webinar series 
• OECD IATA overview page (how NAM data can be integrated) 
• OECD report: concepts and available guidance related to IATA (PDF)

In the European Union, animal use in science is governed by frameworks grounded in the 3Rs principle—Replacement, Reduction, Refinement—with Directive 2010/63/EU as a central legislative pillar. The Directive and related EU/EMA materials emphasize improving animal welfare standards and promoting the development and validation of alternative approaches that can reduce or replace animal procedures when scientifically feasible.

External links

• Directive 2010/63/EU (EUR-Lex, PDF) 
• European Commission overview: “Animals in science” and the 3Rs 
• EMA page referencing Directive 2010/63/EU and 3Rs expectations in medicines development

The regulatory landscape for cardiac NAM platforms is dynamic but structured. Integration pathways emphasize rigor, transparency, and context-specific application rather than categorical substitution of traditional approaches.

Stakeholders evaluating cardiac NAM systems should consider alignment with established regulatory principles, documented performance characteristics, and clearly articulated translational objectives.